PULSE BIOSCIENCES, INC.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
PLSE$55.12-5.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net loss | $(18,581) | $(16,795) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 88 | 117 |
| Amortization of intangible assets | 167 | 166 |
| Stock-based compensation | 1,912 | 5,681 |
| Non-cash lease expense | 308 | 274 |
| Write-off of deferred issuance costs | 281 | — |
| Other | 62 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 55 | — |
| Inventory | (70) | (30) |
| Prepaid expenses and other current assets | (129) | (281) |
| Other non-current assets | 3 | (1) |
| Accounts payable | (148) | 712 |
| Accrued liabilities | 1,832 | (3,043) |
| Lease liabilities, net | (375) | (321) |
| Net cash used in operating activities | (14,595) | (13,521) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (33) | (45) |
| Net cash used in investing activities | (33) | (45) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock under employee stock purchase plan | 465 | 352 |
| Proceeds from exercises of warrants, net of issuance costs | 130 | 14,075 |
| Proceeds from exercises of stock options | 1,674 | 380 |
| Payment of deferred issuance costs in relation to registration statements | (57) | — |
| Net cash provided by financing activities | 2,212 | 14,807 |
| Net (decrease) increase in cash and cash equivalents | (12,416) | 1,241 |
| Cash and cash equivalents at beginning of period | 80,735 | 118,038 |
| Cash and cash equivalents at end of period | $68,319 | $119,279 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Proceeds from exercise of warrants and stock options not yet received | $88 | $— |
| Unpaid issuance costs in relation to registration statements | $111 | $— |
| Unpaid amounts related to purchase of equipment | $28 | $26 |
| Unpaid warrant issuance costs | $3 | $11 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.